This is a repository copy of *Insulin-like Growth Factor 1 Analogs Clicked in the C Domain: Chemical Synthesis and Biological Activities*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/130986/

Version: Published Version

**Article:**
Macháčková, Kateřina, Collinsová, Michaela, Chrudinová, Martina et al. (7 more authors) (2017) *Insulin-like Growth Factor 1 Analogs Clicked in the C Domain: Chemical Synthesis and Biological Activities*. JOURNAL OF MEDICINAL CHEMISTRY. pp. 10105-10117. ISSN 0022-2623

https://doi.org/10.1021/acs.jmedchem.7b01331

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Insulin-like Growth Factor 1 Analogs Clicked in the C Domain: Chemical Synthesis and Biological Activities

Kateřina Machačková,† Michaela Collinsova,† Martina Chrudinová,† Irena Selicharová,† Jan Picha,† Miloš Buděšínský,† Václav Vaněk,† Lenka Záková,† Andrej M. Brzozowski,‡ and Jiří Jiráček*†‡

†Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic
‡York Structural Biology Laboratory, Department of Chemistry, The University of York, Heslington, York YO10 5DD, United Kingdom

Supporting Information

ABSTRACT: Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid protein hormone, with key impact on growth, development, and lifespan. The physiological and clinical importance of IGF-1 prompted challenging chemical and biological trials toward the development of its analogs as molecular tools for the IGF-1 receptor (IGF1-R) studies and as new therapeutics. Here, we report a new method for the total chemical synthesis of IGF-1 analogs, which entails the solid-phase synthesis of two IGF-1 precursor chains that is followed by the Cu(I)-catalyzed azide–alkyne cycloaddition ligation and by biomimetic formation of a native pattern of disulfides. The connection of the two IGF-1 precursor chains by the triazole-containing moiety, and variation of its neighboring sequences (Arg36 and Arg37), was tolerated in IGF-1R binding and its activation. These new synthetic IGF-1 analogs are unique examples of disulfide bonds’ rich proteins with intra main-chain triazole links. The methodology reported here also presents a convenient synthetic platform for the design and production of new analogs of this important human hormone with non-standard protein modifications.

INTRODUCTION

Human insulin and related insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) are small protein hormones, with a key impact on basal metabolism, growth, development,1–3 lifespan,4,5 as well as being implicated in diabetes and cancer.6,7 Hence their central biological importance and involvement in many relevant human pathologies require efforts toward the development of specific analogs of these hormones for studies of the interactions and signaling with respective insulin- and IGF-receptors (IR, IGF-1R) and their applications as new therapeutics.8–10 The recombinant production of insulin and IGFs in E. coli, or in yeast, was an obvious choice,11–15 but did not easily allow the incorporation of non-coded amino acids and unusual structural motifs, which could facilitate more directed structure–activity studies of the hormones and their rational modifications. Moreover, the total chemical synthesis of these proteins, especially of IGF-1 and -2, remains a very challenging task.13

The single-chain organization, fold, and disulfide bond pattern of IGF-1/IGF-2 is similar to proinsulin, a prohormone of insulin, but they are significantly longer (70, 67, and 86 residues, respectively) than both insulin chains (21 and 30 amino acids). Therefore, their solid-phase synthesis is challenging and inefficient as demonstrated by only few early reports on the total chemical synthesis of IGF-1 analogs.14–16 Nevertheless, elegant studies employed a combination of shorter protein fragments by a native ligation for the synthesis of human proinsulin,17 single chain “ester” insulin,18,19 and IGF-1 analog.20 The complexity of the synthesis of these hormones is highlighted further by only one report on the total chemical synthesis of IGF-2.21 Therefore, our aim here was to develop a new methodology for the chemical synthesis of IGF-1 analogs as a feasible alternative for the production of single-chain insulin-like hormones, and one that would allow easy incorporation of non-standard amino acids or other unusual structural motifs.

As the solid-phase synthesis of a single, 70-amino acid chain of IGF-1 is inefficient, in this work we combined the solid-phase synthesis of two shorter precursor IGF-1 fragments with their ligation by a Cu(I)-catalyzed 1,3-dipolar cycloaddition of azides and alkynes,22–24 followed by the biomimetic formation of the native pattern of disulfide bridges. Cu(I)-catalyzed 1,3-dipolar cycloaddition of azides and alkynes is a birhogonal reaction, also called a “click” chemistry, which leads to the formation of 1,4-disubstituted 1,2,3-triazoles. This reaction has become widely used25 in organic, medicinal, and, especially, peptide chemistry,26 as 1,2,3-triazole is a motif with the structural and electronic characteristics similar to those of the peptide bond.27,28 The synthesis of insulin and insulin-like proteins is difficult due to the necessity to form three disulfide bridges. Therefore,
a number of sophisticated methods of insulin synthesis have been developed, usually with an orthogonal protection of cysteines (e.g., in refs 29 and 30 and reviewed in ref 31) and a directed, stepwise formation of disulfides. A similar strategy was developed for other proteins from the insulin family, such as relaxins, DILP, INSL peptides,32–36 and cone snail insulin.37 An alternative, and straightforward, method for the formation of disulfides starts with the simultaneous deprotection of all six cysteines (from e.g. S-sulfonate protected forms) and pairing by a slow air oxidation. This approach takes advantage of the intrinsic biomimetic ability of insulin chains to adopt a natural conformation and a correct coupling of disulfides.18,38–43 In this study, we used the strategy of biomimetic formation of disulfides for the synthesis of IGF-1 analogs.

The biological functionality aspect of this work was focused on the role and modifications of the IGF-1 C domain, specifically, at its Arg36 and Arg37 sites. The C domain of IGF-1 (residues 30–41, Figure 1) was found to be important for its functionality,44–46 as the double Arg36-Arg37 → Ala36-Ala37 mutation severely impaired binding of this mutant to the IGF-1 receptor (IGF-1R)47 and to IGF binding protein 1 (IGFBP-1), which contributes to the regulation of IGF-1 bioavailability.48 In addition, a double Arg36-Arg37 → Glu36-Glu37 substitution also indicated a partial antagonism of this analog, that is, its still effective binding to IGF-1R, but an impaired receptor signaling and tumorigenesis.49

Interestingly, the connectivity, that is, well-defined electron density for residues Arg36-Arg37-Ala38, and, generally, for this central part of the C domain, was frequently missing in several crystal structures of human free, and IGFBP-bound, IGF-1 (Figure 1).51–53 It was postulated then that the pair of these basic arginine side chains may constitute an in vivo proteolytic cleavage site. Although the presence of Arg36 and Arg37 in the IGF-1 C domain is important for an efficient binding to IGF-1R, it was not known whether the cleavage of the Arg36-Arg37 peptide bond impairs hormone binding to IGF-1R or if the resulting two-chain IGF-1 is still able to effectively activate IGF-1R. For this reason, we produced a two-chain IGF-1 analog here as well, which is disconnected between sites Arg36 and Arg37.

Together, we designed, synthesized, and characterized one two-chain IGF-1 analog and three single-chain IGF-1 analogs with a connecting triazole bridge between, or in, sites 36 and 37 to probe the feasibility of their synthesis and to test the impact of these modifications on the biological activities of these analogs. In one of the analogs, Met59 was mutated to Nle59 to prevent oxidation of Met. The in vitro functional properties of the analogs were characterized by the determination of their binding affinities to the IGF-1R, insulin receptor isoform A (IR-A), and their receptor-activation potencies. The IR-A receptor was used here as an IR isoform that, in contrast to its IR-B isoform, is a relatively good binder of IGF-1 and, especially, of IGF-2.12,54,55

## RESULTS

### Synthesis.

The primary structures of peptide precursors and analogs are shown in Figure 2, and the respective synthetic pathways are overviewed in the Supporting Information Figures S1–S4.

**Two-Chain IGF-1 Analog.** First, a two-chain human IGF-1 was prepared, referred to as analog 1, which has a native IGF-1 amino acid sequence, with the same pattern of the disulfide bonds, but it has a split Arg36-Arg37 peptide bond. Hence, analog 1 consists of chain 1-36 and chain 37-70, with all N-termini and C-termini being in the free amine or carboxylic acid forms, respectively (Figure 2).

The individual chains of the analog were prepared by a standard solid-phase synthesis, and the free SH groups of cysteines were converted to S-sulfonates (chains 1a and 1b, Figure 2) immediately after the cleavage of Trt protecting groups (Figure S1). The chains were recombined (i.e., disulfides formed) to give analog 1 with approximately 0.6% yield (0.2 mg) by a procedure described previously.42,43

**Single-Chain IGF-1 Analogs.** We designed the strategy of the solid-phase peptide synthesis of two shorter IGF-1 chains with β-amido-alanine or propargyl glycine at their C- or N-termini, respectively, followed by their ligation by the Cul-catalyzed azide–alkyne cycloaddition.22–24 The final synthetic step consisted of the simultaneous biomimetic formation of the native pattern of all three disulfide bridges, as in analog 1.

The analog 2 was synthesized first (Figures 2 and S2). The synthesis started with the preparation of the chain 2a, as in which the C-terminal Arg36 was replaced by β-amido-alanine carboxamide, and the chain 2b, in which N-terminal Arg37 was replaced by propargyl glycine. Both chains were “clicked”, and the single-chain (Acm-protected) precursor 2c was purified by RP-HPLC. Finally, the Cys-protecting acetamidomethyl (Acm) groups were cleaved, and the analog 2 was allowed to fold by air-induced oxidation.

Next, we synthesized the similar analog 3 from the chains 2a, 3a, and 3b (Figures 2 and S3). The only difference between analogs 2 and 3 was that Met59 was substituted in 3 for norleucine (Nle) to prevent the observed oxidation of Met59.
side chain. Finally, we designed and made analog 4 (from the chains 4a, 4b, and 4c, Figures 2 and S4), in which Arg36 was preserved, the triazole link was formed between sites 37–38, with an additional Arg at the position 39; these modifications resulted in an analog that is two amino acids longer than native IGF-1.

In general, the chains with propargyl glycine at the N-terminus (2b, 3a, and 4b) gave better yields (15–18%) than the azido chains 2a and 4a (6–13%). The preparation of the precursor 2a was hampered by the formation of some byproducts, which were identified as aspartimides (racemized) at positions Asp20 and Arg21 (see analyses and model experiments described in Supporting Information). This problem was largely solved by the use of Fmoc-Asp(OEpe) instead of Fmoc-Asp(OtBu), and the yield improved from 6% to 10%, respectively. We also observed the generation of a byproduct during the synthesis of the peptide 2b, due to the oxidation of Met59 to methionine sulfoxide. This prompted synthesis of analog 3, for which the chain 3a with Met59Ne mutation was used. Although this resulted in a better purity of the crude product 3a, the yields of HPLC purified peptides 2b and 3a were similar (18% and 15%, respectively). Therefore, the native Met59 was retained in peptide 4b, with only a marginal oxidation of the final product.

Our first attempts (Figure S1) at the click ligation of the azido and alkyne precursor chains were performed as described previously,27,43 with cysteines protected as S-sulfonates. However, we have not succeeded to isolate the desired products here: None of the reaction conditions used (CuBr/THPTA/DIPEA, CuBr/THPTA/DIPEA, CuI/DIPEA, CuSO4/ascorbic acid/THPTA, or CuSO4/ascorbic acid in different organic or aqueous solvents with or without chaotropic agents) was successful, that is, compatible with the use of S-sulfonates.

Therefore, the strategy for an efficient disulfide pairing was changed, and all subsequent precursor peptides were synthesized with cysteines protected as Acm groups. Different conditions for the click reactions were investigated, but the only effective setup consisted of an excess of CuSO4/ascorbic acid in fBuOH/water, and this methodology75 was employed for the preparation of peptide chains 2c, 3b, and 4c. The effect of different molar ratios of chain precursors for the synthesis of 2c and 4c was also tested, and it was observed that...
However, this was ine ... products, and the oxidation of the peptide, and its biomimetic folding, and the cycloadditions at equimolar ratio of the precursor chains were isolated by RP-HPLC. The typical yields of this last synthetic step were about 8% (0.5 mg) for 3b, 16%, 18%, and 7% for 3c, 3d, and 3e, respectively, after HPLC purification. The final part of the synthetic work was focused on the optimization of an efficient, and proper/native, formation of the disulfide bonds in single-chain precursors 2c, 3b, and 4c. Initially, an access of iodine in an acetic/hydrochloric acid solution was not compatible with Cu⁺ catalyzed click reaction and that simultaneous cleavage of six Acm-protecting groups in molecules of precursors with an access of I₂ was ineffective and had to be rectified by the use of silver triflate, followed by the removal of Ag⁺ with a gaseous H₂S.

Functional Characterization of the analogs. Binding Affinities to the Receptors. The analogs 2–4, and human insulin and IGF-1 as controls, were tested for their binding to human IGF-1R in membranes of mouse fibroblasts and to human IR-A in membranes of human IM-9 lymphocytes (Table 1, with the representative binding curves in Figures S5 and S6, respectively).

The two-chain analog 1 has significantly impaired binding for IGF-1R of only about 3.5% of the native IGF-1. Similar low binding (4.8%) was also detected for a single-chain analog 3, in which Arg36 and Arg37 were replaced with β-azido-alanine and proparglylglycine, respectively, connected by a triazole link, and with MetS9Nle mutation. Interestingly, analog 2, a “wild-type” homologue of 3 with preserved native Met59, showed markedly stronger 20.8% affinity than analog 3. The insertion of Arg36 and Arg39 in analog 4, adjacent to the connecting triazole-containing 37–38 moiety, further enhanced IGF-1R binding affinity of this analog to almost 25% of the native IGF-1 binding.

Native human IGF-1 has only 1.0% binding affinity for IR-A compared to human insulin, but all analogs were even significantly weaker than human IGF-1 in binding to this receptor (Table 1).

<table>
<thead>
<tr>
<th>Analog</th>
<th>Kᵣ ± SD [nM] (n) for human IGF-1R in mouse fibroblasts</th>
<th>Relative binding affinity for human IGF-1R [%]</th>
<th>Kᵣ ± SD [nM] (n) for human IR-A in IM-9 lymphocytes</th>
<th>Relative binding affinity for human IR-A [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human IGF-1</td>
<td>0.24 ± 0.10 (5)³</td>
<td>100 ± 42</td>
<td>23.8 ± 11.5 (3)³</td>
<td>1.0 ± 0.5</td>
</tr>
<tr>
<td>Human insulin</td>
<td>291.8 ± 54.3 (3)³</td>
<td>0.08 ± 0.01</td>
<td>0.24 ± 0.05 (3)³</td>
<td>100 ± 21</td>
</tr>
<tr>
<td>2c</td>
<td>6.74 ± 2.62 (3)²</td>
<td>3.56 ± 1.38 **</td>
<td>48.2 ± 5.0 (3)³</td>
<td>0.41 ± 0.04 *</td>
</tr>
<tr>
<td>3c</td>
<td>5.04 ± 2.31 (3)³</td>
<td>4.76 ± 2.18 **</td>
<td>113 ± 53 (3)³</td>
<td>0.21 ± 0.09 *</td>
</tr>
<tr>
<td>4</td>
<td>0.49 ± 0.12 (3)²</td>
<td>24.5 ± 6.0 ***</td>
<td>75.1 ± 6.2 (3)³</td>
<td>0.43 ± 0.04 **</td>
</tr>
</tbody>
</table>

*The values of Kᵣ and relative binding affinities (relative-receptor-binding affinity is defined as (Kᵣ of human insulin or IGF-1/Kᵣ of analog) × 100) of human IGF-1, insulin, and the analogs were determined for human IGF-1R in membranes of mouse fibroblasts and human IR-A in membranes of human IM-9 lymphocytes. Asterisks indicate that binding of the ligand differs significantly from that of IGF-1 (*p < 0.05; **p < 0.01; ***p < 0.001).

<table>
<thead>
<tr>
<th>Analog</th>
<th>Kᵣ ± SD [nM] (n)</th>
<th>Relative binding affinity for human IGF-1R [%]</th>
<th>Kᵣ ± SD [nM] (n)</th>
<th>Relative binding affinity for human IR-A [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human IGF-1</td>
<td>0.24 ± 0.10 (5)³</td>
<td>100 ± 42</td>
<td>23.8 ± 11.5 (3)³</td>
<td>1.0 ± 0.5</td>
</tr>
<tr>
<td>Human insulin</td>
<td>291.8 ± 54.3 (3)³</td>
<td>0.08 ± 0.01</td>
<td>0.24 ± 0.05 (3)³</td>
<td>100 ± 21</td>
</tr>
<tr>
<td>1</td>
<td>6.74 ± 2.62 (3)²</td>
<td>3.56 ± 1.38 **</td>
<td>48.2 ± 5.0 (3)³</td>
<td>0.41 ± 0.04 *</td>
</tr>
<tr>
<td>2</td>
<td>1.15 ± 0.45 (4)²</td>
<td>20.8 ± 8.1 **</td>
<td>48.3 ± 7.5 (3)³</td>
<td>0.25 ± 0.04 *</td>
</tr>
<tr>
<td>3</td>
<td>5.04 ± 2.31 (3)³</td>
<td>4.76 ± 2.18 **</td>
<td>113 ± 53 (3)³</td>
<td>0.21 ± 0.09 *</td>
</tr>
<tr>
<td>4</td>
<td>0.49 ± 0.12 (3)²</td>
<td>24.5 ± 6.0 ***</td>
<td>75.1 ± 6.2 (3)³</td>
<td>0.43 ± 0.04 **</td>
</tr>
</tbody>
</table>
In general, the abilities of the analogs to stimulate autophosphorylation of IGF-1R and phosphorylation of intracellular Akt protein paralleled their IGF1-R binding affinities. The lowest IGF-1R autophosphorylation was observed for the two-chain analog 1 (4% binding) and for analog 3 with Met59Nle substitution (5% binding). However, interestingly, the analog 2 that lacks Arg36 and Arg37 activates IGF-1R somehow more strongly than analog 4, which has Arg36 and Arg39 (Figure 3A), despite their reversed binding affinities of 21% and 24%, respectively. The ability of these analogs to activate/phosphorylate Akt protein follows this trend, although the differences between 2 and 4 are less significant here and similar to the native IGF-1 (Figure 3B). We compared the data measured for analogs 2 and 4, using the two-tailed t test to determine the statistical signficance of the observed differences, and only the stimulation of autophosphorylation of IGF-1R in transfected fibroblasts appeared statistically significant ($p = 0.02$), while the difference in binding activities was negligible ($p = 0.82$). In general, it appears that the transfected cells (Figure 3A,B) respond more...
sensitively to the stimulation with analogs than the non-transfected cells (Figure 3C,D), and this trend is visible especially in Akt activation (Figure 3B,D). It seems that higher sensitivity of the transfected cells alleviates the differences in binding affinities of analogs.

All analogs are also less potent than native IGF-1 in the stimulation of IR-A autophosphorylation in IR-A-transfected cells (Figure 3E).

Finally, the dose–response curves of IGF-1R autophosphorylation ability of analogs 1−4 and IGF-1 (Figure 3F) indicate that all analogs are weaker than IGF-1, where analog 2 is the strongest and analog 1 is the weakest, without a major difference between 3 and 4; all in general agreement with the previous results.

■ DISCUSSION

Chemistry. The low yield (0.6%) of the recombination reaction, that is, a biomimetic formation of disulfides, for analog 1 is similar to the rather poor yields of some insulin analogs prepared previously and is significantly lower than typical yields for native human insulin (~10%).43 The poor folding ability of two separate chains of IGF-1 is also reflected in the complexity of the byproducts in the reaction mixture, where we identified, for example, a misfolded, inactive, but correct molecular mass, analog; the active analog 1 was found there as a rather minor peak (Figure S9). Misfolded and inactive IGF-1 molecules, specifically with “swapped” pairs of disulfides, that is, Cys6-Cys47 and Cys48-Cys52, instead of the correct Cys6-Cys48 and Cys47-Cys52, were identified previously in preparations of synthetic IGF-1 and its analogs.20 However, the particularly poor yield of 1 clearly indicates the importance of a single-chain form of IGF-1 for its effective folding. Nevertheless, the amounts of analog 1 were sufficient for its biological characterization, especially with the recycling of chains 1a and 1b and repetition of the reaction.

We assumed that the single-chain IGF-1 analogs, with six free -SH groups, will oxidize themselves to a native conformation and that better folding properties of the single, rather than two-chain, IGF-1 analogs can be expected. However, as mentioned above, the 70-amino acid chain of IGF-1 is too long for an efficient solid-phase peptide synthesis. Therefore, we investigated here the possibility of connecting two IGF-1 fragments by Cu²⁺-catalyzed 1,3-dipolar cycloaddition of azides and alkynes, which would generate 1,2,3-triazole in the main-chain of IGF-1 analog. A similar approach was used by Valverde et al.27 to connect three fragments of cysteine-protease protein inhibitor cystatin (98 amino acids). However, this did not require the formation of native disulfide bonds in this protein. As 1,4-disubstituted 1,2,3-triazoles are considered to be good mimics of the peptide bond,28 it might be possible that their incorporation into the peptide chain in the IGF-1 C domain could be tolerated by IGF-1R. We were also encouraged here by our similar approach in the cross-linking of insulin B-chain with 1,2,3-triazole bridges, in which some highly potent IR analogs were obtained.55

Our first attempts at the clicking of two IGF-1 fragments involved the use of IGF-1 fragment 1−36 with β-alanine alanine at position 36 and the IGF-1 fragment 37−70 with the propargyl glycine at position 37; all cysteines in these peptides were protected as S-sulfonates, which assured their good solubility and better separation on the HPLC. However, all our experiments (not shown) for connecting these fragments by Cu¹⁺-catalyzed click reaction were unsuccessful (Figure S1). We concluded that the S-sulfonate groups are incompatible with the reaction, probably due to the S-sulfonate-copper chelation, which could lead to an undesired Cu-mediated folding of IGF-1 chains and steric blocking of the azido and alkyne groups, making them inaccessible for cycloaddition.

For this reason, we changed the Cys-protection strategy, synthesizing peptide chains with amidomethyl-protected cysteines, assuming that the Acm protection should not interfere with the clicking step, offering also several different alternative deprotections.61 Unfortunately, the first synthesis of 2a was hampered by a considerable amount of other, hardly separable, byproducts, identified as racemized aspartimides at positions Asp20-Arg21 (i.e., peptide 2ax, see Figures S2, S12, and S28). The appearance of Asp-Arg aspartimides is rather rare, but not unusual in peptide chemistry,52 as the Arg(CPb)/Cys(Acm) protection strategy may promote this side reaction to a greater extent.62 To test such a scenario in our chemical environment, we performed a model experiment (Supporting Information, pp 27−28) in which, with a model peptide 7, Phe-Val-Cys(Acm)-Gly-Asp(OBz)-Arg(Peb), we were able to generate and characterize (Figures S29, S30 and Scheme S1, Tables S1−S3) racemized aspartimides that were similar to the ones found in 2ax. Therefore, we used a Fmoc-Asp(OEpe) derivative,64 which helped to eliminate this problem in 2a and 4a. Hence, it seems that the formation of Asp20-Arg21 aspartimide in 2ax was both sequence and side-chain protection-type dependent, as such byproducts were not observed in 1a, 1b, 3a, and 4b.

As mentioned above, the effective reactions and isolation of the products in the cycloaddition step required a reaction setup with a high excess of CuSO₄/d-ascorbate in water-IBuOH,65,67 but the addition of some click accelerators65,66 or reactions in organic solvents55 did not lead to the desired products. It is possible that the participation of bulky copper chelating agents like TBTA or THPTA is not favorable for steric reasons, if large peptide precursors are used. The failure of CuBr or CuI/DIPEA strategy in DMF could be due to a need for an effective protein hydration that is better in water-IBuOH. Although all reactions performed here were ineffective if they were scaled up above 2−4 mg per chain, some amount of the precursors could be recycled, and the reactions repeated. Both single-chain peptides without arginines in the proximity of the azido and alkyne precursor residues (2c and 3b) gave better yields than peptide 4c with the triazole-neighboring arginines. This could be due some steric shielding of the azido and alkyne moieties by the bulky arginine side chains.

Overall, we were able to prepare full-length IGF-1 chains on a preparative scale, still within reasonable yield ranges (7−18%). Our results underline the difficulty of click reactions where both precursors are large peptides, or proteins, compared to click reactions with small peptides/molecules, which usually proceed quickly and quantitatively.25,26

The final synthetic steps, that is, the deprotection of cysteines and the formation of physiological S−S bridges, were crucial for the success of the synthesis. Interestingly, the use of iodine in acetic acid/HCl was not successful here, due to an incomplete cleavage of the Acm groups. One of the reasons for this could be the presence of six Acm groups accumulated in each molecule of the precursor, while only two Acm groups are usually simultaneously deprotected by I₂ for a directed formation of the disulfide.56 For this reason, we used silver triflate, instead of I₂, for the cleavage of the Acm groups, without the purification of an intermediate product. Interest-
ingly, this three-step procedure was relatively effective and successful, providing 6–8% yields for analogs 2 and 3, which are comparable to our yields of syntheses of human insulin from its separate A and B chains (~10%). However, calculated for a single folding step, they were also much better than the ~0.6% yields for the two-chain IGF-1 analog 1. The less effective (1.7%) folding of analog 4 may result from the presence of Arg36 and Arg39 in this analog and, consequently, from a longer C domain than in 2 and 3. It seems that the insertion of two additional Arg residues, rather than the presence of the triazole-containing connecting moiety, lowered the folding efficiency of this IGF-1 precursor. The folding of 2–4 was accompanied by the appearance of inactive misfolded “swapped” products (Figure S16), but to a lesser extent than in the case of 1 (Figure S9), certainly due to the single-chain character of precursors for 2–4.

The clicked polypeptides reported here are, to our knowledge, unique examples of the use of triazole-forming chemistry for the preparative production of large peptides/small proteins (relative molecular weights about 8000 Da), with a native pattern of disulfide bridges. The middle position of the connecting triazole bridge in the protein main chain further validates the results. Moreover, the only few examples of true proteins with main-chain triazoles that were reported did not contain disulfide bridges, which present additional challenges to such an approach.

**Biology.** Analog 1 retained some IGF-1R binding affinity, but its binding potency was severely impaired (3.5%) in comparison with the potency of the native IGF-1 (Table 1). This strongly suggests that the cleavage of Arg36-Arg37 peptide bond, if it occurs in vivo, is not a part of IGF-1 processing, but is rather a degradation-like step of this hormone, which leads to a much less active protein. Whether such cleavage represents some physiological attenuation of IGF-1 activity cannot be excluded, but it requires further, complex studies on this hormone, especially on in vivo-derived material.

The incorporation of the triazole bridge formed from β-azido-alanine at 36 and propargylglycine at 37 reduced the binding affinity of the analog 2 to about 21% of the binding affinity of the native IGF-1. However, this affinity drop is less significant than the effect of Ala36-Ala37 mutation of this hormone, which reduced its receptor binding to about 5%.47 Therefore, it seems that the loss of Arg36-Arg37 in 2 is, somehow, compensated for by the triazole ring and/or the neighboring ethyl carboxymido (at 36) and ethyl amino (at 37) moieties. Some insight into the functional differences of the analogs 1–4 may be facilitated by a direct comparison of their connecting motifs shown in Figure 4. In 2, this motif is three atoms longer than the peptide bond of the native IGF-1, and the only difference between analog 2 and 3 is Met59Nle mutation in analog 3. This exchange reduced the IGF-1R affinity of the analog 3 to 5%, in agreement with the work of Shooter et al.68 where Met59Phe mutation resulted in the 17-fold decrease in IGF-1R binding. Therefore, analog 3 further highlights the importance of the sulfur atom in Met59 for receptor binding, which is not compensated for in 3 by the Nle alkyl chain. The highest IGF-1R binding affinity in the series from Table 1 was found for analog 4 (almost 25% of native IGF-1). However, statistical analysis (see above) showed that the difference in binding affinities of 4 and 2 is not significant, hence, both analogs are rather similar in this aspect. Although analog 4 retains arginines in the C-loop, they are at sites 36 and 39, not at their native positions 36–37 (Figures 2 and 4).

![Figure 4: Comparison of the connecting motifs at positions 36–37 or 37–38 in analogs 2–4 with the native human IGF-1. Cα atoms are marked by residue numbers.](image)

Therefore, the Cα atoms of the arginines in 4 are separated by eight extra backbone atoms plus triazole ring and carboxamide and amino moiety. Interestingly, this extension did not reduce the binding affinity of this analog in comparison with analog 2, indicating a relative tolerance of IGF-1R for the modifications in this part of the C domain. However, it is also possible that at least one of the Arg36/Arg39 in 4 (e.g., Arg36) occupies a similar position on the receptor as one of the natives Arg36–37. This result opens up new possibilities for the use of different side chains, and motifs, at positions adjacent to the triazole ring, that is, 36 and 37 in 2 and 37 and 38 in 4. However, such approaches depend on the development of available functionalized azides and alkynes suitable for the solid-phase peptide synthesis.

All analogs 1–4 have reduced binding affinities for the isoform A of the insulin receptor (Table 1) compared to native IGF-1. However, it seems that this decrease (21–43% of native IGF-1) is lower than for the IGF-1R (3–25% of native IGF-1), indicating that the C domain of IGF-1 is less important for IR-A binding than for an effective hormone complex formation with the IGF-1R.

The abilities of analogs 1–4 to induce the autophosphorylation of IGF-1R and IR-A and to activate the downstream Akt generally reflected their binding affinities for these receptors. This trend is especially visible in non-transfected fibroblasts, with a natural population of IGF-1R (Figure 3C,D). It seems that the high non-natural concentration of IGF-1R in IGF-1R-transfected fibroblasts is behind their higher sensitivity to the stimulation by the analogs, rather than differences in binding affinities of human IGF-1 for rat and human IGF-1R; this level up the differences in binding affinities of analogs. The reason for this phenomenon could be in the “disproportional” populations/distributions of receptors and intracellular signaling proteins. In this respect, the native fibroblasts, with naturally lower population of IGF-1R, seem to be a better model. The only apparent exception here could be observed in a higher receptor stimulating activity of analog 2 than of analog 4 despite slightly reverse binding affinities. This “discrepancy” is interesting, but should be treated with caution, due to the low statistical significance of the differences between biological properties of analogs 2 and 4 mentioned above. Nevertheless,
we observed a similar phenomenon in the case of insulin-IGF hybrids, that is, human insulin molecules with the B chain prolonged for C domain amino acids of human IGF-2. However, it is rather difficult to explain such a discrepancy without a structure of the analogs in a complex with the receptor, and even crystal/NMR structures of the analogs would provide only very limited clues. It is possible that only a complex with the so-called site 2 of IGF-2 receptor would shed light on the slightly different activation/binding observed here, and only the structures of insulin and IGF-1 complexed with site 1 of the IR are currently available. Nevertheless, it was observed that differential binding kinetics of insulin-like analogs, that is, slower or faster $k_{on}$ or $k_{off}$ rates, can influence their metabolic or mitogenic biological responses, this could be the case of the apparent di

Finally, analogs 1–4 do not appear to possess the properties of IGF-1R antagonists or partial antagonists, as was observed for the IGF-1 Glu36-Glu37 mutant. It is possible then that the antagonism observed for the Glu36-Glu37 IGF-1 analog results from a reversed, negatively charged glutamic acid side chains, instead of the arginine basic guanidine groups, and that the replacement of the Arg36-Arg37 pair, by moieties shown in Figure 4, is not sufficient to elicit a similar antagonistic effect.

## CONCLUSIONS

In summary, we developed a new method for the total chemical synthesis of human IGF-1 analogs, which entails a solid-phase synthesis of two IGF-1 precursor chains, and their ligation by Cu

catalyzed azide–alkyne cycloaddition chemistry. This relatively straightforward methodology presents a viable synthetic alternative to the previously established IGF synthetic strategies, which employed native ligation. The connection of two IGF-1 precursor chains by triazole-containing moieties was relatively well tolerated by IGF-1R and IR-A, both in terms of receptor binding and activation, and can thus represent a convenient and relatively straightforward synthetic strategy for the design of new analogs of this important human hormone with non-standard protein modifications. We also found that the disruption of the connectivity of the IGF-1 Arg36-Arg37 peptide bond deactivates this protein, hence it is unlikely that such cleavage represents a maturation step of this hormone in vivo.

## EXPERIMENTAL SECTION

Unless otherwise stated, reagents and materials were obtained from commercial suppliers (Sigma-Aldrich-Fluka, Merck) and used without purification.

### Solid-Phase Peptide Synthesis

Peptide chains were prepared by manual solid-phase synthesis in plastic syringes, equipped with a Teflon frit or with ABI433A peptide synthesizer. Standard Fmoc amino acids (Iris Biotech, Gmbh, Germany) were used, and couplings were done with HBTU/DIPEA or DIC/HOBt reagents in DMF. Usually two couplings (60 min) with Fmoc-amino acids (3–5 equiv for manual synthesis and 10 equiv for automated synthesis) were done. In manual synthesis, the efficiency of the couplings was monitored by the Kaiser test, and the amount of cleaved Fmoc group (20% piperidine in DMF for 5 and 20 min) was determined spectrophoto-metrically (extinction coefficient 7040 M$^{-1}$ cm$^{-1}$ at 301 nm). Fmoc-Asp(OIpe)-OH was prepared as described in the Supporting Information and used for the syntheses of 2a and 4a. Fmoc-$\beta$-azido-(S)-Ala-OH was prepared as described by Picha et al.

The peptide chains with the C-terminal $\beta$-azido-(S)-Ala carboxyamide, 2a and 4a, were synthesized on Rink amide MM LL resin or Nova Peg Rink amide (Merck-Novabiochem), respectively. Fmoc-(S)-propargylglycine-ONH$_2$ was purchased from Sigma-Aldrich-Fluka. The peptide chains 1a, 1b, 2b, 3a, and 4b with a free carboxy terminus were synthesized on Wang-ChemMatrix LL resins, preloaded with Fmoc-Ala or Fmoc-Arg(Pbf) (PCAS BioMatrix Inc.). The peptides were cleaved with 91.5% TFA, 2.3% H$_2$O, 2.3% thioanisole, 2.3% phenol, 1.15% DODT, and 0.45% TIS for 2–4 h. Subsequently, the crude peptides were precipitated from the cold diethyl ether (in at least 10-fold excess), centrifuged, and dried. The precipitates of crude peptides 1a and 1b were immediately converted to S-sulfonates and subsequently desalted, as previously described in detail.[24] Finally, all peptide chains were purified by RP-HPLC.

### Peptide and Compound Characterization

The precursor peptides (1a, 1b, 2a, 2b, 2c, 3a, 3b, 4a, 4b, and 4c), and the resulting IGF-1 analogs 1–4 were purified and the purity of compounds analyzed by RP-HPLC. HRMS spectra of all compounds, peptides, and analogs were obtained on a FTMS mass spectrometer LTQ-orbitrap XL (Thermo Fisher, Bremen, Germany) in electrospray ionization mode. The purity of target compounds 1–4 was ≥95% (RP-HPLC, HR-MS). The identity and purity of analogs 1–4 were furthermore verified by N-terminal sequencing. Analytical data for all peptide precursors, IGF-1 analogs 1–4, and conditions for NMR measurements of 2a and model compounds 7 are provided in the Figures S7–S30, Tables S1–S3, and Scheme S1. Melting points of compounds 5 and 6 were determined on a Boetius block and are uncorrected. $^1$H and $^{13}$NMR spectra of compounds 5 and 6 were measured on a Bruker AVANCE-600 spectrometer (H at 600.13 MHz, 13C at 150.9 MHz) in CDCl$_3$, DMSO-$d_6$, CD$_2$OD, or D$_2$O solution at 300 K. The 2D-H,H-COSY, 2D-H,C-HSQC and 2D-H,C-HMBC spectra were recorded and used for the structural assignment of proton and carbon signals. IR spectra of compounds 5 and 6 were recorded on Bruker IFS 55 Equinox apparatus.

#### Peptide 1a

The yield (RP-HPLC) was 4.3% (27 mg). HRMS-ESI: Monoisotopic $M_r$ = calcd for C$_{169}$H$_{225}$N$_{49}$O$_{53}$S$_{4}$ 4000.701, found 4000.677.

#### Peptide 1b

The yield (RP-HPLC) was 12.2% (51 mg). HRMS-ESI: Monoisotopic $M_r$ = calcd for C$_{165}$H$_{220}$N$_{39}$O$_{52}$S$_{4}$ 4146.683, found 4146.665.

### Analog 1

Recombination of chains 1a (17 mg, 4.27 µmol) and 1b (33 mg, 7.95 µmol) was done according to the procedure previously described in detail.[24] The typical yield of the analog 1 (relative to chain 1a as the limiting component of the reaction) after RP-HPLC purification was about 0.6% (0.2 mg). HRMS-ESI: Monoisotopic $M_r$ = calcd for C$_{163}$H$_{213}$N$_{48}$O$_{52}$S$_{4}$ 3761.597, found 3761.617.

#### Peptide 2a

When Fmoc-Asp(OBz)-OH was used, the yield (RP-HPLC) was 6.2% (22 mg). HRMS-ESI: $M_r$ = calcd for C$_{171}$H$_{221}$N$_{48}$O$_{53}$S$_{4}$ 3937.815, found 3937.818. The aspartimide derivative of 2a (with an aspartimide bond at Asp20-Arg21, that is, peptide 2ax, see in the Supporting Information) was purified (Figure

---

**Scheme 1**

Reagents, conditions, and yields (a) DIC, DMAP, 3-ethyl-3-pentanol, DCMS 0 °C 1 h, then rt 48 h (91%); (b) 10% Pd/C, H$_2$, 10 psi, methanol 12 h; (c) Fmoc-OSu, NaHCO$_3$, water and dioxane, 0 °C 1 h, then rt overnight (65% over two steps).
silica gel using a linear gradient of ethyl acetate in petroleum ether. Yield 5.8 g (91%). Colorless oil. Rf = 0.74 (20% ethyl acetate/toluene).

If Fmoc-Asp(OEt)-OH (6) was used for the synthesis, the yield (RP-HPLC) was 10.1% (120 mg). HRMS-ESI M⁺ for C_{17}H_{25}N_{3}O_{7}S_{2} was 3919.805, found 3919.809.

If Fmoc-Asp(OEt)-OH (6) was used for the synthesis, the yield (RP-HPLC) was 10.1% (120 mg). HRMS-ESI M⁺ for C_{17}H_{25}N_{3}O_{7}S_{2} was 3919.805, found 3919.809.

Stably transfected with either human

Article

silica gel using a linear gradient of ethyl acetate in petroleum ether. Yield 5.8 g (91%). Colorless oil. Rf = 0.74 (20% ethyl acetate/toluene).

When diketopiperazine 4 was used as a protecting group, yield (RP-HPLC) was 8.8% (1.7 mg). HRMS-ESI M⁺ for C_{17}H_{26}N_{3}O_{7}S_{2} was 3937.815, found 3937.819. Undesired aspartimide byproduct was not found in this case.

In general, the click reactions were performed according to the protocol previously published by Vikova et al. with a few modifications. Briefly, the typical reaction mixture containing the linear peptide 2a (4 mg, 1.02 μmol) and 2b (2 mg, 0.49 μmol), which were dissolved in 4.5 mL of tert-butanol/water mixture (2:1, v/v), Next, the ascorbic acid (5.5 μmol) and CuSO_{4}·5H_{2}O (4.80 μmol) were added in a minimum volume of water (the mixture was freshly prepared). The reaction mixture proceeded with stirring at 40 °C overnight. The precipitated product was removed from the reaction mixture by centrifugation and was purified using RP-HPLC (C4 column). The typical yield (RP-HPLC, relative to the chain 2b as the limiting component of the reaction) was about 16% (0.6 mg). HRMS-ESI M⁺ for C_{14}H_{24}N_{3}O_{7}S_{2} was 3978.7756, found 3978.7768.

4b. The yield (RP-HPLC) was 18.5% (75 mg). HRMS-ESI M⁺ for C_{14}H_{24}N_{3}O_{7}S_{2} was 4049.941, found 4049.945.

Peptide 2c. In general, the click reactions were performed according to the protocol previously published by Vikova et al. with a few modifications. Briefly, the typical reaction mixture containing the linear peptide 2a (4 mg, 1.02 μmol) and 2b (2 mg, 0.49 μmol), which were dissolved in 4.5 mL of tert-butanol/water mixture (2:1, v/v), Next, the ascorbic acid (5.5 μmol) and CuSO_{4}·5H_{2}O (4.80 μmol) were added in a minimum volume of water (the mixture was freshly prepared). The reaction mixture proceeded with stirring at 40 °C overnight. The precipitated product was removed from the reaction mixture by centrifugation and was purified using RP-HPLC (C4 column). The typical yield (RP-HPLC, relative to the chain 2b as the limiting component of the reaction) was about 16% (0.6 mg). HRMS-ESI M⁺ for C_{14}H_{24}N_{3}O_{7}S_{2} was 3978.7756, found 3978.7768.

**Scheme 1.**

(25)-N-((9H-Fluoren-9-ylmethoxy)carbonyl)aspartic acid 4-(3-ethylpent-3-yl)ester 6. Intermediate 5 (6.9 g; 15.1 mmol) was charged to a nitrogen flushed glass pressure bottle, dissolved in 80 mL of methanol, and then 500 mg of Pd/C was added. The mixture was vigorously stirred and allowed to react under the atmosphere of hydrogen (1.5 psi) at RT for 12 h. TLC analysis (eluent: ethyl acetate/toluene) revealed that the starting compound had completely disappeared. The catalyst was filtered off through Celite, and the filter cake was washed with 100 mL of methanol. The filtrate was evaporated in vacuo to give 3.5 g of light brown residue, which was immediately dissolved in 50 mL of aqueous solution of NaHCO_{3} (2.5 g; 30.2 mmol). The flask was placed in an ice bath, and Fmoc-OSu (5.1 g; 15.1 mmol) in 50 mL of dioxane was added dropwise under stirring. After the addition of the total amount of Fmoc-OSu, stirring continued for 1 h at 0 °C and then overnight at room temperature. Thereafter, 10% aqueous solution of citric acid was added to the reaction mixture until pH ~3~4 was reached, followed by 200 mL water. The solution was transferred to a separator funnel and extracted with 4 × 100 mL of ethyl acetate. Combined organic layers were washed consecutively with 2 × 50 mL water, 2 × 50 mL brine, and dried over anhydrous Na_{2}SO_{4}. The filtrate was evaporated to afford a dark yellow oil, which was purified by flash chromatography on silica gel, using a linear gradient of ethyl acetate in toluene. Yield 4.5 g (65% over two steps). Bright yellow semisolid. Rf = 0.67 (ethyl acetate/acetone-ethanol-water 6/1/1, v/v). HRMS (ESI) M⁺, 478.228. 478.220.

**Cell cultures.** Human IM-9 lymphocytes and NIH/3T3 mouse fibroblasts were obtained from ATCC. Mouse fibroblasts derived from IGF-1R knockout mice and stably transfected with either human IGF-1 receptor (IGF-1R), or human insulin receptor isoform A (IR-A), were kindly provided by Professor A. Belfiore (University of Magna Grecia, Catanzaro, Italy) and Professor R. Baserga (Thomas Jefferson University, Philadelphia, Pennsylvania, USA). IM-9 cells were grown in RPMI 1640 media with 10% fetal bovine serum. IGF-1R and IR-A cells were grown in DMEM media with 5 mM glucose with 10% fetal bovine serum and 0.3 mg/mL puromycin. NIH/3T3 cells were grown in DMEM media with 10% bovine serum albumin. All media
were further supplemented with 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin, and the cells were grown in humidified air with 5% CO₂ at 37 °C.

Receptor-Binding Studies. Human IM-9 Lymphocytes (Human IR-A Isoform). Receptor-binding studies with the insulin receptor in membranes of human IM-9 lymphocytes (containing only human IR-A isoform) were performed and Kd values determined as described previously.2,45 Binding data were analyzed using the Excel algorithms specifically developed for the IM-9 cells system in the laboratory of Prof. Pierre De Meyts (A. V. Groth and R. M. Smykno, Hagedorn Research Institute, Denmark, a kind gift from P. De Meyts), using the method of a non-linear regression and a one-site fitting program, taking into account the potential depletion of the free ligand. Each binding curve was determined in duplicate, and the final dissociation constant (Kd) of an analog was calculated from at least three (n ≥ 3) binding curves (Kd values), determined independently. The dissociation constant of human 125I-insulin (PerkinElmer) was set to 0.3 nM.

Mouse Embryonic Fibroblasts (Human IGF-1R). Receptor binding studies with the human IGF-1 receptor in membranes of mouse embryonic fibroblasts derived from IGF-1R knockout mice and transfected with human IGF-1R were performed as described previously.2,45 Binding data were analyzed, and the dissociation constant (Kd) was determined with GraphPad Prism 5 software, using a non-linear regression method and a one-site fitting program, taking into account potential depletion of free ligand. Each binding curve was determined in duplicate, and the final dissociation constant (Kd) of an analog was calculated from at least three (n ≥ 3) binding curves (Kd values) determined independently. The dissociation constant of human 125I-IGF-1 (PerkinElmer) was set to 0.2 nM. Here we should note that the use of bovine serum albumin (e.g., Sigma-Aldrich A6003) void of “IGF-binding-like” proteins, which interfere with these binding assays, is essential for the preparation of the binding buffer.74

The significance of the changes in binding affinities of the analogs, related to the binding of IGF-1, was calculated using a two-tailed t test.

Receptor Phosphorylation Assay. Cell Stimulation and Detection of Receptor phosphorylation. Both were performed as previously described.55 In brief, mouse fibroblasts (NIH/3T3, IR-A and IGF-1R) were seeded in 24-well plates (Schoeller) and incubated for 24 h. Cells were afterward starved for 4 h in serum-free media. The cells were stimulated with 10 nM concentrations of the ligands for 10 min. Proteins were routinely analyzed, using immunoblotting and horseradish peroxidase-labeled secondary antibodies (Sigma-Aldrich). The membranes were probed with antiphospho-IGF-1-IR (Tyr1135/1136)/IR (Tyr1150/1151) and antiphospho-Akt (Thr308) (C316SE) (Cell Signaling Technology). The blots were developed using the SuperSignal West Femto maximum sensitivity substrate (Pierce) and analyzed using the ChemiDoc MP Imaging System (BioRad). Each experiment was repeated four times. The data were expressed as phosphorylation of receptor relative to the human insulin (IR-A) respective IGF-1 (NIH/3T3 and IGF-1R) signal. The significance of the changes in stimulation of phosphorylation of receptors and related Akt-stimulation by the IGF-1 was calculated using one-way analysis of variance.

Ligand-Dose Response IGF-1R Autophosphorylation Levels. The levels were determined using In-Cell Western assay7 adapted for Chemiluminescence. The IGF-1R cells were plated at 20,000 cells/well in white 96-well Brand plates cell grade (Brand GMBH, Germany) and incubated for 24 h. Cells were afterward starved for 4 h in serum-free media and stimulated with dilutions of ligands (0–100 nM) for 10 min. After incubation, the medium was discarded, and the cells were fixed in 3.75% freshly prepared formaldehyde for 20 min. Cells were permeabilized with 0.1% Triton-X-100 in PBS for 5 min and blocked with 5% BSA in T-TBS for 1 h. Plates were incubated with antiphospho-IGF-1-IR (Tyr1135/1136)/IR (Tyr1150/1151) overnight at 4 °C. Then plates were thoroughly washed with TBS, incubated with peroxidase-labeled antirabbit secondary antibody (Sigma) for 1 h at room temperature, and washed again. SuperSignal West Femto maximum sensitivity substrate was added to each well, and chemiluminescence was detected using the ChemiDoc MP Imaging System after 5 min. Data were subtracted from background values and expressed as contribution of phosphorylation relatively to the 10 nM IGF-1 signal. Control wells and wells stimulated with 10 nM IGF-1 were in triplicates on each plate. Experiments were repeated at least four times. Log(agonist) vs response curve fitting of data was carried out with GraphPad Prism 5 software.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.7b01331.


AUTHOR INFORMATION

Corresponding Author

*Phone: +420 220183 441. E-mail: jiracek@uochb.cas.cz.

ORCID

Andrzej M. Brzozowski: 0000-0001-7426-8948
Jiří Jiráček: 0000-0003-8484-2773

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by Medical Research Council Grant MR/K000179/1 (to A.M.B.). This work was also supported by the Research Project of the Czech Academy of Sciences RVO:61388963 (for the Institute of Organic Chemistry and Biochemistry).

ABBREVIATIONS USED

Ac, acetamidomethyl; c₅₀, molar concentration; DIC, N,N'-diisopropylcarbodiimide; DILP, Drosophila insulin-like peptide; DIPEA, N,N-diisopropylethylamine; DMF, dimethylformamide; DODT, 2,2’-(ethylenedioxy)diethanethiol; Epe, ethylpentyl; INS, insulin-like peptide insulin receptor isofrom A; IGF, insulin-like growth factor; IR-B, insulin receptor isofrom B; IGF-1R, receptor for IGF-1; HBTU, N,N,N',N'-tetramethylenepiperazine-1-yluronium hexafluorophosphate; HOBt, hydroxybenzotriazole; M, relative molecular weight; HRMS-ESI, high-resolution mass spectrometry electrospray ionization; RP-HPLC, reverse-phase high-performance liquid chromatography; TBT, tris[(1-benzyl-1H-1,2,3-triazole-4-yl)methyl]amine; TFA, trifluoroacetic acid; THPTA, tris(3-hydroxypropyltriazolylmethyl)amine; TIS, trisopropylsilane; Tr, trityl

REFERENCES


(18) Sohma, Y.; Hua, Q. X.; Whittaker, J.; Weiss, M. A.; Kent, S. B. H. Design and folding of [Gluc(A4)(O(β)-Thr(B30))] insulin ("ester insulin"): a minimal proinsulin surrogate that can be chemically converted into human insulin. Angew. Chem., Int. Ed. 2010, 49, 5489−5493.


(68) Slaby, R.; Andersen, A. S.; Brandt, J. IGF-I binding to the IGF-I receptor is affected by contaminants in commercial RSA: The contaminants are proteins with IGF-I binding properties. Horm. Growth IGF Res. 2008, 18, 267–274.

(69) Aguilar, H. N.; Zielnik, B.; Tracey, C. N.; Mitchell, B. F. Quantification of rapid myosin regulatory light chain phosphorylation...